AstraZeneca and GSK doubled down on China collaborations with Sino Biopharmaceuticals via separate respiratory deals. AstraZeneca is licensing an ex-China PDE3/4 inhibitor candidate, while GSK is granting Sino ownership in China of marketed respiratory medicines Trelegy and Anoro, reinforcing how UK pharma is using regional manufacturing and distribution relationships to protect growth.